相关实验视频

Updated: Sep 9, 2025

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

来自免疫细胞的CAR外体:克服瘤免疫治疗障碍的新兴纳米前沿

Xiaoyan Zhao¹, Bin Zhao², Yan Sun³

¹Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Frontiers in immunology

|September 4, 2025

概括

化学抗原受体 (CAR) 外体为固体瘤提供了一种新的无细胞疗法,克服了传统CAR细胞疗法的局限性. 这些工程外体显示出更安全,更有效的癌症免疫疗法.

科学领域:

免疫学
纳米医学
癌症学

背景情况:

化学抗原受体 (CAR) 工程细胞疗法对血液癌症有效,但在固体瘤中面临挑战,包括毒性和瘤透不良.
固体瘤中CAR-T,CAR-NK和CAR-M细胞疗法的局限性需要创新的方法.

研究的目的:

审查与固体瘤的CAR细胞疗法相关的挑战.
突出CAR-Exosomes作为下一代癌症免疫治疗平台的潜力.
总结CAR-Exosomes的最新进展和临床转化策略.

主要方法:

对CAR细胞疗法和CAR-Exosomes的当前文献进行系统审查.
对CAR外体特征,向机制和治疗途径的分析.
对CAR-Exosomes的生物安全和工程策略的评估.

主要成果:

CAR-外基因组从母 CAR 细胞中继承瘤向能力.
CAR外体具有低免疫性,增强组织透性和药物载荷能力等优势.
最近的进展涵盖了CAR-Exosome的分子特征,准,杀死途径,安全性和工程.

结论:

在固体瘤中,CAR-Exosomes是一个有前途的无细胞治疗策略,解决了传统CAR细胞治疗的局限性.
结合纳米医学和细胞疗法,CAR-Exosomes为癌症免疫治疗提供了潜在的更安全,更有效的方法.
进一步的研究和临床转化策略对于实现CAR-Exosomes的全部潜力至关重要.

关键词:

美国癌症没有细胞外基因组免疫疗法

更多相关视频

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes

Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes

Published on: May 24, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Overview of Exosomes

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...